Back to search results

Investigating AI's Impact on Prostate Cancer Detection

This study is looking at whether using Artificial Intelligence (AI) can help doctors better find prostate cancer on MRI scans before a biopsy. The AI tool, called AI Rad Companion Prostate MRI (AIRC), helps radiologists interpret MRI images. You might be able to join if you are between 55 and 80 years old, have a PSA (prostate-specific antigen) level between 3-10 ng/mL, and are planning to have a prostate biopsy after an MRI due to suspected prostate cancer. We want to see if the AI helps radiologists more accurately identify areas that might be cancer. The study's success will be measured by how well radiologists, with and without AI, can predict the presence of significant prostate cancer on MRI. The current recruitment status is unclear.

Study design
This is an interventional study planning to enroll 150 participants. It compares how radiologists interpret MRI scans alone versus when they are helped by AI.
What's involved
Your participation in the study will involve about an hour to review the consent form. All other study procedures, like the MRI and biopsy, are part of your standard medical care.
Compensation
Not stated in the trial record.
Follow-up
Your MRI results will be evaluated one time, up to 30 days after you join the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07084779

Investigation of Impact of AI on Prostate Cancer Workflow

Recruiting
NAAges 55–80InterventionalScreening
Case Comprehensive Cancer Center
~150 participants
Updated 2026-05-15 on ClinicalTrials.gov
What's tested:AI

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Readers' (radiologists') mean quadrant-level area under the receiver operating characteristic curve (AUC) in predicting the presence or absence of clinically significant prostate cancer (csPCa)
Measured over One-time MRI, up to 30 days post-enrollment in study.

Conditions

Prostate Cancer
Prostatic Neoplasm
Cancer of the Prostate
Neoplasms, Prostate

Explore related trials

Prostate CarcinomaKLK3 Gene

Where it's being run

1 sites across 1 states
Ohio1

Study leadership

  • Andrei Purysko, MD · PRINCIPAL_INVESTIGATOR · Case Comprehensive Cancer Center, Cleveland Clinic

Who to contact

Andrei Purysko, MD
[email protected]
216-445-9005
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Plan of care is to undergo a biopsy of the prostate after a pre-biopsy MRI
Age 55-80
Prostate-specific antigen (PSA) between 3-10 ng/mL
No prior diagnosis or treatment of prostate cancer

Exclusion

Pre-biopsy MRI is of low quality
PI-QUAL score of 1 using PI-QUAL version 2

What this trial measures

  • Readers' (radiologists') mean quadrant-level area under the receiver operating characteristic curve (AUC) in predicting the presence or absence of clinically significant prostate cancer (csPCa)One-time MRI, up to 30 days post-enrollment in study.

    csPCa is defined as Gleason grade group ≥ 2.